Home Your basket
• Treatment failures in ben...
   Price 10.50 €
• Utility of positron emiss...
   Price 8.50 €
• Wegener granulomatosis mi...
   Price 14.00 €
• Notes on voice and speech...
   Price 8.50 €
• Bilateral cochlear implan...
   Price 5.50 €
• Apology for the biplane c...
   Price 10.50 €
• Cephalic vein access for ...
   Price 10.50 €
• Nasal polyposis: long ter...
   Price 10.50 €
• Otosclerosis among patien...
   Price 10.50 €
• Rejuvenation of the eye: ...
   Price 10.50 €
• Dermatofibrosarcoma protu...
   Price 10.50 €
• The three-stage frontal f...
   Price 14.00 €
• Revision ossiculoplasty: ...
   Price 10.50 €
• Perceptual assessment of ...
   Price 10.50 €
• Efficacy and safety of mo...
   Price 10.50 €
• A survey of current wound...
   Price 5.50 €
• Ambulatory stapedectomy: ...
   Price 8.50 €
• Evaluation of the handica...
   Price 10.50 €
• Sentinel lymph node biops...
   Price 15.00 €
• The frontal pneumosinus d...
   Price 8.50 €
• Vertebro and cranio veino...
   Price 14.00 €
• Reverse phonation: Pathol...
   Price 8.50 €
• Otoplasty: Special attent...
   Price 8.50 €
• Cosmetic radiofrequency...
   Price 10.50 €
• Interests of multimedia s...
   Price 10.50 €
• Traditional and emerging ...
   Price 10.50 €
• A comparative acoustic st...
   Price 5.50 €
• Frontal sinus osteoma com...
   Price 5.50 €
• Adenomatoid hamartoma of ...
   Price 5.50 €
• Hearing results in stapes...
   Price 10.50 €
• Bell's palsy: treatment b...
   Price 5.50 €
• Neuroplasticity in the au...
   Price 10.50 €
• Interest of MIBI scintigr...
   Price 10.50 €
• Cowden syndrome: Otolaryn...
   Price 12.00 €
• Diagnosis and treatment o...
   Price 10.50 €

Total Order 342.00 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 1 - 2016 o

RHINOLOGY

Efficacy of nasal irrigation with 2.2% hypertonic seawater in the treatment of chronic rhinosinusitis in adults


Authors : Strnad P, Skoupá J, HornÍk P, Cimrová H, Cerná V. (Prague)

Ref. : Rev Laryngol Otol Rhinol. 2016;137,1:3-10.

Article published in english
Downloadable PDF document english



Summary : Objective: To evaluate the efficacy and the tolerance of nasal irrigation with 2.2% hypertonic seawater in the treatment of chronic rhinosinusitis (CRS) in adults either used as mono­therapy, or in combination with intranasal corticosteroids. Method: In this prospective, open-label, multicenter controlled trial, 238 patients diagnosed with CRS were randomly assigned to three groups: group 1 with intranasal corticosteroids (steroid), group 2 with nasal irrigation with hypertonic seawater (seawater) and group 3 with a treatment combining intranasal corticosteroids at lower dose and seawater (steroid+seawater). Nasal index score (NIS), patient health status, intranasal corticosteroids intake, tolerance were assessed at baseline, week 2 and 6, and satisfaction at week 6. Results: NIS was significantly improved in group 2 (seawater) and group 3 (steroid+seawater) at week 2 (p< 0.001 in both groups) and week 6 (p< 0.0001 in both groups) compared to group 1 (steroid), along with a significant decrease of intranasal corticosteroids (p < 0.0001). Patient health status improved in group 2 and group 3 at week 2 (p= 0.1040 and p< 0.001 respectively) compa­red to control (steroid), and this improvement was significantly greater in both groups at week 6 compared to steroid group (p< 0.0001). Conclusion: Hypertonic nasal irrigation is an effective treatment for CRS in adults. It significantly improved nasal symptoms and allowed a signi­fi­cant decrease of intranasal corticosteroids use while improving patient health status. Nasal irrigation with 2.2% hypertonic seawater could therefore be considered as first-line treatment for CRS, either as monotherapy or in combination with lower dosage of intranasal corticosteroids.

Price : 15.00 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE